About: Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Latest price: $6.22 (-0.96%)
PHAT NASDAQ Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals Inc share price
Atividade de preço de PHAT
Último preço
$ 6,220
Variação (24h)
-0,06 USD (0,96%)
Volume
3.84M
Volume (média 4 sem.)
-
Abertura
$ 7,00
Variação do dia
$ 5,71 - $ 7,00
Fechamento anterior
$ 6,28
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
PHAT price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals